There is nothing inherently wrong with profiting from old drugs. It depends on the drug in question, its efficacy and safety, and the context within which it was approved and priced in the market. Problems can arise if the newly branded drug has limited effectiveness and its price is exorbitant.
Turning Very Old Drugs Like Makena Into Profits: Regulatory Reform Needed
